{"success":true,"data":{"pressRelease":{"id":"59693","rtpr_id":"nWkr8lCngm","ticker":"OSSD","exchange":"Nasdaq Stockholm","all_tickers":["OSSD"],"title":"Annual General Meeting held in OssDsign AB","author":"Cision","published_at":"2026-06-10T08:55:55.388Z","article_body":"OssDsign AB\nOn 9 June 2026, OssDsign AB (publ) held its annual general meeting for 2026.\nBelow is a summary of the resolutions passed at the annual general meeting\n(complete information and documents regarding the decisions of the meeting are\navailable on the company's website www.ossdsign.com).\n\nThe annual general meeting resolved:\n\n* to adopt the profit and loss statement and the balance sheet and the group\nprofit and loss statement and the group balance sheet for the financial year\n2025;\n* that the company’s result shall be carried forward in new account and that\nno dividend shall be paid for the financial year 2025;\n* to grant the board members and the CEO discharge from liability for the\nfinancial year 2025;\n* that the board of directors shall consist of five ordinary members without\ndeputy members, to re-elect Christer Fåhraeus, Jill Schiaparelli, David Jern\nand Tomas Blomquist as ordinary board members, election of Per Aniansson as\nnew ordinary board member, and to elect Per Aniansson as new chairman of the\nboard;\n* that a registered accounting firm shall be elected as auditor and to\nre-elect Ernst & Young AB as the company’s auditor;\n* that fees payable to the board members until the end of the next annual\ngeneral meeting shall amount to a total of SEK 1,300,000 out of which SEK\n400,000 shall be paid to the chairman and SEK 300,000 to each of the other\nboard members except for Christer Fåhraeus to whom no board fee is to be\npaid. In addition, it was resolved that fees shall be paid to the board\nmembers serving on the audit committee for the period until the end of the\nnext annual general meeting in a total amount of SEK 120,000, of which SEK\n80,000 shall be paid to the chairman of the audit committee and SEK 40,000 to\nthe other member of the audit committee;\n* that the auditor is to be paid in accordance with approved invoices;\n* on an authorization for the board of directors to increase the share capital\nthrough issuance of new shares, warrants and/or convertible debentures through\nwhich the company’s share capital may be increased by an amount\ncorresponding to not more than twelve (12) per cent of the share capital after\nsuch issue(s);\n* to adopt the board's proposed resolution on (i) implementation of a\nlong-term incentive program for employees and contractors (Warrant Programme\n2026/2029:1) through a directed issue of no more than 3,100,000 warrants of\nseries 2026/2029:1 to the company and/or any of its subsidiaries and approval\nof the subsequent transfer of the issued warrants to certain employees and\ncontractors within the group against payment of the market value of the\noption right or, provided that it does not entail negative tax consequences\nfor the group, free-of-charge, and (ii) cancellation of Warrant Programme\n2025/2028:1 which has not been utilised. Each warrant entitles the holder to\nsubscribe for one (1) new share in the company, as adjusted downwards by\napplication of the mandatory so-called quotient exercise model set forth in\nthe proposed resolution, during the period from and including 1 July 2029\nuntil and including 31 December 2029, against payment of a subscription price\nper new share corresponding to 160 percent of the volume weighted average\ntrading price for the company’s share on Nasdaq First North Growth Market\nduring a period of five (5) trading days before the annual general meeting.\nThe warrants are governed by customary terms and conditions, including any\nadjustments to the subscription price and the number of new shares that each\nwarrant entitles the holder to subscribe for in the event of certain events\naffecting the company.\n\nFor further information, please contact:\n\nMark Waugh, CEO\n+1 (260) 804-1342\nmark.waugh@ossdsign.com\n\nCertified Adviser\n\nThe Company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ)\n\nAbout OssDsign\n\nOssDsign is a developer and global provider of next generation orthobiologics\nproducts. Based on cutting edge material science, the company develops and\nmarkets products that support the body's own healing capabilities, giving\npatients back the life they deserve. The company has a strong presence in the\nU.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in\nStockholm, Sweden.\n\nhttps://news.cision.com/ossdsign-ab/r/annual-general-meeting-held-in-ossdsign-ab%2Cc4360098\n\nAnnual General Meeting held in OssDsign AB\n(https://mb.cision.com/Main/18020/4360098/4143938.pdf)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr8lCngm","title":"Annual General Meeting held in OssDsign AB","author":"Cision","ticker":"OSSD","created":"2026-06-10T08:55:55.388Z","tickers":["OSSD"],"exchange":"Nasdaq Stockholm","article_body":"OssDsign AB\nOn 9 June 2026, OssDsign AB (publ) held its annual general meeting for 2026.\nBelow is a summary of the resolutions passed at the annual general meeting\n(complete information and documents regarding the decisions of the meeting are\navailable on the company's website www.ossdsign.com).\n\nThe annual general meeting resolved:\n\n* to adopt the profit and loss statement and the balance sheet and the group\nprofit and loss statement and the group balance sheet for the financial year\n2025;\n* that the company’s result shall be carried forward in new account and that\nno dividend shall be paid for the financial year 2025;\n* to grant the board members and the CEO discharge from liability for the\nfinancial year 2025;\n* that the board of directors shall consist of five ordinary members without\ndeputy members, to re-elect Christer Fåhraeus, Jill Schiaparelli, David Jern\nand Tomas Blomquist as ordinary board members, election of Per Aniansson as\nnew ordinary board member, and to elect Per Aniansson as new chairman of the\nboard;\n* that a registered accounting firm shall be elected as auditor and to\nre-elect Ernst & Young AB as the company’s auditor;\n* that fees payable to the board members until the end of the next annual\ngeneral meeting shall amount to a total of SEK 1,300,000 out of which SEK\n400,000 shall be paid to the chairman and SEK 300,000 to each of the other\nboard members except for Christer Fåhraeus to whom no board fee is to be\npaid. In addition, it was resolved that fees shall be paid to the board\nmembers serving on the audit committee for the period until the end of the\nnext annual general meeting in a total amount of SEK 120,000, of which SEK\n80,000 shall be paid to the chairman of the audit committee and SEK 40,000 to\nthe other member of the audit committee;\n* that the auditor is to be paid in accordance with approved invoices;\n* on an authorization for the board of directors to increase the share capital\nthrough issuance of new shares, warrants and/or convertible debentures through\nwhich the company’s share capital may be increased by an amount\ncorresponding to not more than twelve (12) per cent of the share capital after\nsuch issue(s);\n* to adopt the board's proposed resolution on (i) implementation of a\nlong-term incentive program for employees and contractors (Warrant Programme\n2026/2029:1) through a directed issue of no more than 3,100,000 warrants of\nseries 2026/2029:1 to the company and/or any of its subsidiaries and approval\nof the subsequent transfer of the issued warrants to certain employees and\ncontractors within the group against payment of the market value of the\noption right or, provided that it does not entail negative tax consequences\nfor the group, free-of-charge, and (ii) cancellation of Warrant Programme\n2025/2028:1 which has not been utilised. Each warrant entitles the holder to\nsubscribe for one (1) new share in the company, as adjusted downwards by\napplication of the mandatory so-called quotient exercise model set forth in\nthe proposed resolution, during the period from and including 1 July 2029\nuntil and including 31 December 2029, against payment of a subscription price\nper new share corresponding to 160 percent of the volume weighted average\ntrading price for the company’s share on Nasdaq First North Growth Market\nduring a period of five (5) trading days before the annual general meeting.\nThe warrants are governed by customary terms and conditions, including any\nadjustments to the subscription price and the number of new shares that each\nwarrant entitles the holder to subscribe for in the event of certain events\naffecting the company.\n\nFor further information, please contact:\n\nMark Waugh, CEO\n+1 (260) 804-1342\nmark.waugh@ossdsign.com\n\nCertified Adviser\n\nThe Company’s Certified Adviser is DNB Carnegie Investment Bank AB (publ)\n\nAbout OssDsign\n\nOssDsign is a developer and global provider of next generation orthobiologics\nproducts. Based on cutting edge material science, the company develops and\nmarkets products that support the body's own healing capabilities, giving\npatients back the life they deserve. The company has a strong presence in the\nU.S. market. OssDsign's share is traded on Nasdaq First North Growth Market in\nStockholm, Sweden.\n\nhttps://news.cision.com/ossdsign-ab/r/annual-general-meeting-held-in-ossdsign-ab%2Cc4360098\n\nAnnual General Meeting held in OssDsign AB\n(https://mb.cision.com/Main/18020/4360098/4143938.pdf)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-06-10T08:55:55.477999237Z","server_sent_at_ms":1781081755478},"received_at":"2026-06-10T08:55:55.532Z","source_url":"https://news.cision.com/ossdsign-ab/r/annual-general-meeting-held-in-ossdsign-ab%2Cc4360098"},"analysis":{"id":"49119","press_release_id":"59693","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"OssDsign held its 2026 annual general meeting, resolving to carry forward results without paying a dividend for fiscal year 2025.\n\nPer Aniansson was elected as the new chairman of the board, replacing the previous leadership, while four existing members were re-elected.\n\nShareholders authorized the board to increase share capital by up to 12% via new shares, warrants, or convertible debt, and approved a new long-term incentive warrant program for 3.1 million warrants.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine AGM: New board chairman installed, no dividend, and standard dilution authorization for small-cap biotech."},"keyFigures":{"customDimensions":{"warrants_issued":3100000,"chairman_fee_sek":400000,"board_fees_total_sek":1300000,"audit_committee_fees_sek":120000,"max_share_capital_increase_pct":12}},"quotedText":"no dividend shall be paid for the financial year 2025","namedEntities":{"people":[{"name":"Christer Fåhraeus","role":"Board Member"},{"name":"Jill Schiaparelli","role":"Board Member"},{"name":"David Jern","role":"Board Member"},{"name":"Tomas Blomquist","role":"Board Member"},{"name":"Per Aniansson","role":"New Chairman of the Board"},{"name":"Mark Waugh","role":"CEO"}],"products":[],"companies":[{"name":"OssDsign AB","ticker":"OSSD"},{"name":"Ernst & Young AB","relationship":"Auditor"},{"name":"DNB Carnegie Investment Bank AB","relationship":"Certified Adviser"}],"dollarAmounts":[{"amount":"SEK 1,300,000","context":"Total board fees"},{"amount":"SEK 400,000","context":"Chairman fee"},{"amount":"SEK 300,000","context":"Fee per ordinary board member"},{"amount":"SEK 120,000","context":"Total audit committee fees"},{"amount":"SEK 80,000","context":"Audit committee chairman fee"},{"amount":"SEK 40,000","context":"Audit committee member fee"}]},"materialImpact":{"score":2,"reasoning":"Routine annual general meeting outcomes. Key changes include a new board chairman (Per Aniansson) and authorization for up to 12% share capital increase plus a new warrant program. No dividend was paid. These are standard corporate governance and capital structure updates for a small-cap biotech."},"tickerRelevance":{"others":[],"primary":"OSSD"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_governance","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"event_type":"board_change","event_type_secondary":["dilution"],"sentiment":"neutral","material_impact_score":2,"narrative":"OssDsign held its 2026 annual general meeting, resolving to carry forward results without paying a dividend for fiscal year 2025.\n\nPer Aniansson was elected as the new chairman of the board, replacing the previous leadership, while four existing members were re-elected.\n\nShareholders authorized the board to increase share capital by up to 12% via new shares, warrants, or convertible debt, and approved a new long-term incentive warrant program for 3.1 million warrants.","key_figures":{"customDimensions":{"warrants_issued":3100000,"chairman_fee_sek":400000,"board_fees_total_sek":1300000,"audit_committee_fees_sek":120000,"max_share_capital_increase_pct":12}},"named_entities":{"people":[{"name":"Christer Fåhraeus","role":"Board Member"},{"name":"Jill Schiaparelli","role":"Board Member"},{"name":"David Jern","role":"Board Member"},{"name":"Tomas Blomquist","role":"Board Member"},{"name":"Per Aniansson","role":"New Chairman of the Board"},{"name":"Mark Waugh","role":"CEO"}],"products":[],"companies":[{"name":"OssDsign AB","ticker":"OSSD"},{"name":"Ernst & Young AB","relationship":"Auditor"},{"name":"DNB Carnegie Investment Bank AB","relationship":"Certified Adviser"}],"dollarAmounts":[{"amount":"SEK 1,300,000","context":"Total board fees"},{"amount":"SEK 400,000","context":"Chairman fee"},{"amount":"SEK 300,000","context":"Fee per ordinary board member"},{"amount":"SEK 120,000","context":"Total audit committee fees"},{"amount":"SEK 80,000","context":"Audit committee chairman fee"},{"amount":"SEK 40,000","context":"Audit committee member fee"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-10T08:56:29.305Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_governance","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low"}},"durationMs":33763,"modelName":"george-droid-qwen-72b"}}